Introduction: ACE2 alternatively converts angiotensin (Ang) II into Ang-(1-7) and Ang I into Ang-(1-9). There is little information in the literature with respect to Ang-(1-9) properties. A number of studies show a link between peptides of the renin-angiotensin system and thrombosis.
Introduction
Renin-angiotensin system (RAS) peptides are involved in the regulation of hemostasis. It has been demonstrated that Ang (angiotensin) II contributes to endothelial dysfunction and arteriosclerosis development. It exerts prothrombotic effects in vivo via angiotensin receptor type 1 (AT 1 ) and increases plasminogen activator inhibitor type 1 (PAI-1) activity. 1 In vitro experiments indicate that Ang I may be converted in humans not only by angiotensin-converting enzyme (ACE) into Ang II or neprylysin into Ang-(1-7), but also ACE2 or other enzymes into Ang-(1-9). 2,3 Snyder et al. showed that the main metabolite of Ang I in platelets is not Ang II but Ang- (1) (2) (3) (4) (5) (6) (7) (8) (9) , which possesses inhibitory activity against ACE. 4, 5 Moreover, in human heart tissue, the main products of Ang I degradation are both Ang- (1) (2) (3) (4) (5) (6) (7) (8) (9) and Ang II. 6 Ang-(1-9) was detected in human plasma 7, 8 and a higher than Ang II concentration of this peptide was found in the kidney. 9 In vivo studies provide more insights into the possible role of Ang- (1) (2) (3) (4) (5) (6) (7) (8) (9) in the regulation of the cardiovascular system. Ocaranza et al. 10 pointed out that Ang-(1-9) may be important in the pathogenesis of myocardial infarction (MI) . They also demonstrated that chronically infused Ang-(1-9) exerts antihypertrophic activity and suggested that pharmacological activation of ACE2/Ang-(1-9) could be a novel therapeutic target in heart failure. 11 Flores-Muñoz et al. showed reduced cardiac fibrosis and altered aortic contraction after Ang-(1-9) treatment, which supports a direct role of this peptide in the RAS pathophysiology. 12 They also observed improved vasorelaxation and increased nitric oxide (NO) bioavailability, and at the same time they found that blood pressure (BP) tended to increase during a stable two-week infusion of Ang- (1) (2) (3) (4) (5) (6) (7) (8) (9) . Earlier data indicated that Ang-(1-9) could mimic the pressor effect of Ang II when administered in vivo. 13 In our recent short-term study we found that Ang-(1-9) exogenously administered into blood circulation may be a source of both peptides, Ang II and Ang-(1-7). 14 Ang-(1-7) acts as a counter-regulatory hormone to Ang II, limiting its pressor, proliferative and angiogenic actions. The effects of Ang-(1-7) are mediated by Ang-(1-7)-specific binding sites, 15, 16 identified later as an endogenous G protein-coupled receptor for Ang-(1-7) (Mas receptor) and can be fully blocked by the selective Ang-(1-7) antagonist D-Ala-Ang-(1-7) (A-779). 17 We have previously demonstrated the opposite effects of these two peptides on venous thrombosis development in renal hypertensive rats. 1, 18 In our recent study Ang-(1-9) showed similar prothrombotic activity to Ang II and promoted arterial thrombosis by platelet activation in rats. 14 Several key questions emerge from the present in vivo data with Ang-(1-9) that should be answered. It is important to investigate whether the Ang-(1-9) effects are similar to Ang II or to Ang-(1-7), and if these peptides are responsible for its effects. In the electrically induced arterial thrombosis model, a significant increase of fibrinogen (Fg) concentration and fibrin generation after Ang-(1-9) infusion was revealed. 14 Thus, it would be interesting if the effect of Ang-(1-9) on hemostasis also involves fibrinolysis. In vitro Ang-(1-9) is a potent competitive inhibitor of ACE 6 and a stimulator of NO release. 19 However, Ang-(1-9), similarly to Ang II, increases nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity. 12 This effect could be responsible for the accumulation of reactive oxygen species, which in turn could enhance adhesion of leukocytes to the endothelial surface. In our previous study we observed increased leukocyte adhesion to the vascular wall after Ang II infusion. 1 In the present work, using a similar experimental model, we try to determine the effect of Ang-(1-9) on venous thrombosis, coagulation and fibrinolysis.
Materials and methods

Animals and ethics
Male Wistar rats (180-200 g) were used in the experiments. Animals were housed in a room with a 12-hour light/dark cycle, in group cages as appropriate and had free access to water and standard rat chow. Rats were anesthetized with pentobarbital (40 mg/kg, intraperitoneally (i.p.)). In some animals two-kidney one-clip (2K-1C) renovascular hypertension was induced by a partial, standardized clipping of the left renal artery, as described previously. 5 Six weeks after surgery, hypertension development was verified by measurement of systolic blood pressure (SBP) in 2K-1C conscious rats weighing 380-420 g, using the "tail cuff" method (Panlab Harvard Apparatus NIPB, Spain). 5 Only hypertensive rats were used in the further experiments. Sham-operated rats (SO) served as a control to 2K-1C hypertensive animals. They receive the same surgical procedure without the clipping of the renal artery.
The procedures involving animals and their care were conducted in conformity with the institutional guidelines that are in compliance with national and international laws and Guidelines for the Use of Animals in Biomedical Research.
Chemicals and drugs
Ang-(1-9) and Ang II (Bachem, Bubendorf, Switzerland), losartan (LOS) (Molekula, Shaftesbury, UK), A-779 (Bachem, Bubendorf, Switzerland), salarasin (Sigma-Aldrich, Lyon, France ), heparin (Heparinum, Polfa S.A., Warsaw, Poland), Tris buffer (Sigma-Aldrich, Poznan, Poland), ethylenediaminetetraacetic acid (EDTA) (Merck, Warsaw, Poland), PAI-1 and t-PA Kits (American Diagnostica Inc, Stamford, CT, USA), pentobarbital (Vetbutal, Biovet, Pulawy, Poland) were used in the study. Reagents to prothrombin time (PT), activated partial thromboplastin time (APTT) and Fg level measurements were bought from HemosIL, Instrumentation Laboratory (Bedford, MA, USA).
Angiotensin 1-9, LOS and A-779 administration
Vehiculum (VEH, 0.9% NaCl) (n = 20) or Ang-(1-9) in doses of 200 (n = 10),400 (n = 13),800 (n = 12) and 1600 pmol/kg/min (n = 13) were infused into the right femoral vein of normotensive rats. Infusions started 10 minutes before the induction of venous thrombosis and were continued for the next two hours. Infusions were given in a volume of 2 ml/kg/h to maintain euvolemia. Doses were chosen according to other pharmacological studies with RAS peptides. LOS, a selective AT 1 antagonist, was administered intravenously (IV) as previously described 1 into the left femoral vein in a dose of 30 mg/kg, five minutes before Ang-(1-9) (n = 8) or VEH infusions (n = 7). A-779 (selective Ang-(1-7) antagonist 15, 16 D-Ala-Ang-(1-7)) was coadministered in a dose of 10000 pmol/kg/min IV as previously described five minutes before Ang-(1-9) (n = 7) or VEH infusions (n = 8). 18 In 2K-1C rats VEH (n = 18) or Ang-(1-9) in doses of 10 (n = 4), 100 (n = 7) and 400 pmol/ kg/min (n = 5) were administered as in normotensive rats.
Mean blood pressure (MBP) measurement
MBP was measured in anesthetized rats directly through a cannula filled with heparin solution (150 IU/ml), placed in the left common carotid artery and connected to a pressure transducer (Hugo Sachs Elektronik, Harvard Apparatus, Germany), as described previously. 1 These animals received an infusion of 0.9% NaCl (VEH) (n = 5), Ang II (400 pmol/ kg/min) (n = 4) or Ang-(1-9) (400 pmol/kg/min) (n = 6) without inducing venous thrombosis.
Venous thrombosis
The venous thrombosis was performed as previously described. 5 Ten minutes after angiotensins or VEH administration, the abdomen was opened and the vena cava was carefully separated from the surrounding tissues and then ligated tightly with a cotton thread just below the left renal vein. Subsequently, the abdomen was closed with a double layer of sutures (peritoneum with muscles and skin separately). After two hours, the abdomen was reopened, the vena cava was carefully dissected, and inspected for the presence of a thrombus. The thrombus was air-dried in 37 o C and after 24 hours its weight was measured. Blood samples were drawn into 3.13% trisodium citrate in a volume ratio of 10:1, then centrifuged at 2000 × g at 4°C for 20 minutes and the plasma was deep-frozen (-70°C) in aliquots of 300 μl until further assays could be performed.
Ang-(1-9) radioligand binding to AT 1 receptor assay
The assay was performed according to Le et al. 20 Briefly, transfected HEK-293 cell membrane homogenates (8 μg protein) were incubated for 120 minutes at 37°C with 0.05 nmol/l ( 125 I)(Sar 1 -Ile 8 ) angiotensin II in the absence or presence of Ang-(1-9) or saralasin as a reference compound in the concentrations from 10 pmol/l up to 1 μmol/l. Nonspecific binding was determined in the presence of 10 μmol/l angiotensin II. Following incubation, the samples were filtered rapidly under vacuum through glass fiber filters (GF/B, Packard). The filters were dried and counted for radioactivity in a scintillation counter (Packard Topcount NXT Scintillation Counter, Surplus Solutions, Fall River, MA, USA). The results were expressed as a percentage of inhibition of the control radioligand-specific binding. The measurement was performed twice.
Thrombus morphology
Ten mm of vena cava with the clot inside were taken out from rats infused with VEH or Ang-(1-9) (400 pmol/kg/ min), and prepared by fixing them in 10% neutral buffered formalin for at least three days and cross-sectioned at 4-μm intervals. Sections were mounted on glass microscope slides and stained with hematoxylin-eosin or May Grünwald-Giemsa for light microscopic analysis. The area of fibrin mixed with platelet aggregates (F+P), trapping red (RBCs) and white blood cells (WBCs), was compared between the two groups using NIS-Elements Advanced Research software kindly provided by Nikon (Warsaw, Poland).
PAI-1 plasma activity and total concentration and t-PA plasma activity measurement
The plasma level of PAI-1 and t-PA were measured by enzymelinked immunosorbent assay (ELISA) in a microtiter plate at 25°C using a microplate-reader (Dynex Technologies, Chantilly, VA, USA) according to the manufacturer's directions and previous studies.
Coagulation parameters and fibrin generation
PT and APTT were automatically determined by optical method (Coag-Chrom 3003; Bio-ksel, Grudziądz, Poland), adding routine laboratory reagents to the collected rat plasma. Fg plasma level was evaluated according to the Clauss method. We used the previously described method, which we modified and adapted for use on laboratory animals to measure fibrin generation. 1 Optical density of a fibrin generation curve was measured via the microplate reader (Dynex Technologies, Chantilly, VA, USA) in oneminute intervals for 15 minutes.
Statistical analysis
The data are shown as mean ± SEM. When calculating the thrombus weight, lack of the thrombus was regarded as 0 mg. To test whether the mean of a variable differs between two groups, the two-tail Mann-Whitney test was used consistently throughout the study. Multiple group comparisons were performed by Kruskal-Wallis nonparametric analysis of variance (ANOVA), followed by Dunn's multiple comparisons test. Correlations were analyzed using a Pearson test. P values of less than 0.05 were considered significant.
Results
The effect of Ang-(1-9) and Ang II on MBP
We observed a noticeable rise in MBP after 20 minutes of Ang-(1-9) infusion, reaching a maximum at the 60th minute. The difference between initial MBP and the 60th-minute value (∆MBP) was significantly greater in Ang II-(24±8 mmHg; p < 0.01) and in Ang-(1-9)-(13±6 mmHg; p < 0.05) infused animals in comparison with VEH-treated animals (-0.2 ± 7 mmHg) ( Figure 1) . The hypertensive effect of Ang-(1-9) was significantly weaker than the effect of Ang II (p < 0.05).
The effect of Ang-(1-9) on thrombus formation
In normotensive animals, Ang-(1-9) infusion resulted in a rise of venous thrombus weight (0.48±0.16, 0.76±0.16, 0.66±0.20 and 0.59±0.12 mg for doses of 200, 400, 800 and 1600 pmol/kg/min, respectively, vs 0.36±0.11 mg in the VEH-treated group; not significant (ns), p < 0.05, ns, ns, Figure 2 ). LOS administered together with Ang-(1-9) in doses of 400 pmol/kg/min reversed the prothrombotic effect of Ang-(1-9) (0.15±0.09 for Ang-(1-9) with LOS vs 0.76±0.16 mg for Ang-(1-9) administered alone; p < 0.01), whereas A-779 did not ( Figure 2 ). LOS (0.28±0.15 mg) or A-779 (0.51±0.31 mg) administered alone did not exert a significant effect on thrombus formation. The incidence of thrombosis in the VEH-treated group was 50%, whereas the Ang-(1-9) 200, 400, 800 and 1600 pmol/kg/min treated group was 62.5%, 92%, 58% and 77%, respectively. In a group treated with Ang-(1-9) and LOS, the incidence of thrombosis was 37%, whereas in a group treated with LOS alone it was 28%. If Ang-(1-9) was co-administered with A-779, the incidence of thrombosis was 42%, whereas in a group treated with A-779 alone it was 37%.
We found that the increase of thrombus weight in the 2K-1C group was more pronounced than in the normotensive rats (Figure 3) . Additionally, the 2K-1C hypertensive VEH-treated group was occluded in 78%, whereas each of the 2K-1C animals treated with Ang-(1-9) in doses of 400 pmol/kg/min had developed venous thrombus.
Ang-(1-9) radioligand binding to AT 1 receptor assay
We found that Ang-(1-9) did not bind to the AT 1 receptor (response lower than 25% in the highest concentration, IC50>1 μmol/l) ( Figure 4) . In contrast, a specific AT 1 inhibitor-salarasin as a reference compound-bound significantly to the AT 1 receptor in the same experimental conditions (IC50 = 0.31 nmol/l).
The effect of Ang-(1-9) infusion on thrombus morphology
Representative examples of the thrombus morphology in the control and Ang-(1-9)-(400 pmol/kg/min) infused rats are presented in Figure 5 . In both groups histological examination revealed similar thrombus consisting of WBCs and RBCs trapped in the fibrin network mixed with platelet aggregates (F+P). As shown in Figure 5 (a1) and (b1), WBCs adhere to and infiltrate into the vascular wall (VW). There was no significant difference in the ratio area of F+P to whole thrombus size between theVEH-and the Ang-(1-9)-treated group.
The effect of Ang-(1-9) on PAI-1 plasma activity and total concentration and t-PA plasma activity
Two hours of infusion of Ang-(1-9) in a dose of 400 pmol/ kg/min significantly increased PAI-1 activity (1.87±0.36 ng/ml for Ang-(1-9) vs 0.91±0.06 ng/ml in the VEHtreated group; p < 0.05) and PAI-1 total concentration (1.34±0.23 ng/ml for Ang-(1-9) vs 0.75±0.07 ng/ml in the VEH-treated group; p < 0.05) in rat plasma (Figure 6(a) ), whereas t-PA activity showed a trend toward decreasing (0.07±0.02 for Ang-(1-9) vs 0.18 ± 0.03ng/ml in the VEH-treated group; p = 0.056) ( Figure 6(b) ). The ratio of t-PA/PAI-1 expressing the overall fibrinolytic balance significantly decreased (p < 0.05) ( Figure 6(b) ). We also observed a significant linear correlation between PAI-1 activity and PAI-1 total concentration (r = 0.754, p < 0.001). LOS inhibited a rise of PAI-1 activity (0.81±0.16 for Ang-(1-9) with LOS vs 1.87± 0.36 ng/ml for Ang-(1-9) administered alone; p < 0.05) induced by Ang-(1-9), whereas A-779 did not ( Figure 6(c) ). LOS administered alone had no effect, whereas A-779 increased PAI-1 activity (1.34±0.19 for A-779 vs 0.91±0.06 ng/ml in the VEHtreated group; p < 0.05).
The effect of Ang-(1-9) on fibrin generation and coagulation parameters
The optical density of the fibrin generation value in the 15th minute in animals infused with Ang-(1-9) in a dose of 400 pmol/kg/min (64.43±3.6%; p < 0.05) significantly increased in comparison with VEH-treated animals (46.09±3.80%). The effect was reversed by LOS (30.74±3.10%; p < 0.001), but not by A-779 (52.78±4.65%) ( Figure 6(d) ). Both LOS (53.8±4.78%) and A-779 (41.2±6.8%) administered alone did not affect fibrin generation. Ang-(1-9) had no effect on APTT (23.82±4.53 vs 25.81±3.10 seconds in VEH-treated animals) and PT (19.51±2.74 vs 20.65±3.88 seconds in VEH-treated animals). We observed a trend toward increased Fg plasma concentration (2.26±0.07 vs 2.01±0.05ng/ml only in VEHtreated animals; p = 0.0559).
Discussion
Since some of the studies showed favourable effects of Ang-(1-9) similar to that of Ang-(1-7) on endothelial function, we tried to verify if its direct cellular activity contributes to the systemic hemodynamic response. We found a slight but statistically significant increase of BP one hour after infusion of Ang-(1-9). The effect was much weaker than after administration of Ang II. Our result is in line with the study showing a trend to BP increase after long-term IV infusion of Ang-(1-9) into stroke-prone spontaneously hypertensive rats or a pressor response observed after injection into the cerebroventricles of rats. 12, 13 This evidence indicates that Ang-(1-9) itself or through its metabolites may contribute to the rise in peripheral vascular resistance.
Next, we tried to determine the influence of this peptide on the thrombotic process and fibrinolysis. We have previously shown that Ang-(1-9) dose-dependently promoted development of electrically induced arterial thrombosis and that platelet activation was involved in this effect. This time, we chose the experimental model of stasis-induced venous thrombosis that more closely resembles pathological conditions of thrombus formation in humans. Additionally, this model also separates the hemodynamic and hemostatic effects of the studied substances because of the minor relationship between arterial and venous blood pressure. Using this model, we have previously demonstrated that ACE-Is (captopril), AT 1 receptor antagonists, such as LOS, or Ang-(1-7) exert a strong antithrombotic effect 18, 21, 22 and that Ang II enhances thrombosis. 1 Ang-(1-9) enhanced venous thrombosis development. We found a similar, but more pronounced, prothrombotic effect in the hypertensive animals, in which endothelial dysfunction is progressively developing. Further, our experiments were conducted with normotensive animals, so our results would be relevant to the larger population and not only renovascular hypertensive subjects. Surprisingly, increasing a dose did not potentiate but moderately reduced the effect, suggesting that the effect of the Ang-(1-9) on venous thrombosis is more complex. That kind of dose-response curve is not a unique feature in the studies on angiotensins. Ding et al. showed that Ang II potentiates platelet aggregation in the concentration of 10 -11 M, whereas increasing concentration to 10 -7 M reverses the effect. 23 We have also previously observed a similar "bell-shaped" curve of a dose-response effect after infusions of Ang III and Ang IV in the same thrombosis model. 1 This is a characteristic feature of many compounds, and may reflect the ability of their metabolites to exert biological activity. We previously found that after administration of the Ang-(1-9), two peptides: Ang II and Ang-(1-7) are produced. We thought antithrombotic Ang-(1-7) 18 could be responsible for the lack of prothrombotic effect of Ang-(1-9) administered in higher doses. Cell culture-based studies indicate that the majority of Ang II effects contributing to thrombosis development are related to the AT 1 receptor. 24 Indeed after blocking of AT 1 receptor with LOS, the effect of Ang-(1-9) was reversed. The results of radioligand binding assay showed a very poor binding of Ang-(1-9) to AT 1 , excluding the possibility that Ang-(1-9) itself enhances thrombosis. The prothrombotic effect was sustained if Ang-(1-9) was co-administered with the Ang-(1-7) antagonist A-779, which did not support the hypothesis that Ang-(1-7) mediates the effects of Ang-(1-9) in vivo. Flores-Muñoz et al. demonstrated that Ang-(1-9) does not act via the Mas receptor in vitro. 25 Furthermore, Ocaranza et al. 11 observed that the antihypertrophic effect of Ang-(1-9) also was not dependent on Ang-(1-7) because the Mas receptor antagonist A-779 had no effect. The augmentation of venous thrombosis and the increase of BP observed in our experiments after infusion of Ang-(1-9) indicates that Ang II must be involved in the acute in vivo effects of Ang-(1-9). Indeed, Ang II may be formed from Ang-(1-9) in the kidney. 26 We have previously found Ang II in the blood of rats immediately after Ang-(1-9) administration. 14 It must also be emphasized that our present study was a short-term observation (two hours) and compensatory responses may be excluded. Wakefield et al. described completely different time-dependent mechanisms of thrombus formation and resolution after vena cava ligation, 27 thus the effect of Ang-(1-9) may be different in long-term studies. Furthermore, the activity of renin or ACEs in thrombotic animals can be altered, similarly to other studies with diabetic or MI rats. 11, 26 At this point our experiments demonstrated that the acute prothrombotic activity of Ang-(1-9) is probably mediated by Ang II acting via the AT 1 receptor.
In our previous study the prothrombotic effect of Ang II was mainly related to the disturbed fibrinolytic balance. 1 According to many studies Ang II stimulates release of PAI-1 from cultured human endothelial cells and increases PAI-1 mRNA expression in cultured rat aortic smooth muscle cells. 28 In the present study the bell-shaped effect of Ang-(1-9) on thrombosis was accompanied by the same changes of PAI-1 activity and total concentration of PAI-1 in plasma and the opposite in the plasma activity of t-PA. Similarly to the prothrombotic action, the increase of PAI-1 activity was mediated by the AT 1 receptor. Interestingly, the increase of PAI-1 activity observed after blocking Ang-(1-7) with A-779 suggests the possible role of endogenous Ang-(1-7) in fibrinolysis regulation. We have also observed a significant linear correlation between PAI-1 activity and PAI-1 total concentration, indicating that the changes were probably related to release of PAI-1 from storage, such as platelet granules. Indeed, Ang-(1-9), similarly to Ang II, may activate platelets 14 and thus may enhance the release of platelet mediators.
Light microscopy revealed that formation of fibrin, incorporating WBCs and RBCs, plays an important role in the venous thrombosis process. Similarly to Ang II, Ang-(1-9) infusion increased fibrin generation via the AT 1 receptor in rat plasma. Since the standard coagulation parameters such as PT and APTT did not change after Ang-(1-9) infusion, it seems that the fibrinolysis impairment could contribute to the accelerated fibrin formation.
Conclusions
Our present study revealed a novel important property of a poorly known RAS peptide-Ang-(1-9). Using a living animal model, we have demonstrated that the prothrombotic effect of Ang-(1-9) is mediated by Ang II via the AT 1 receptor. Additionally, we have shown that Ang-(1-9) does not bind to the AT 1 receptor. The main reason for enhanced thrombus formation seems to be uncontrolled fibrin formation due to the disturbed balance between t-PA and PAI-1. Taking into account the possible protective effects of Ang-(1-9), such as NO release or inhibition of heart hypertrophy and fibrosis, 11, 12 the selective inhibition of Ang II formation from Ang-(1-9) could be a new therapeutic strategy.
